Evidence map›Paper›PMID 42166704›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Jia Xiang Jin, Varun R Ginde, Stefanie Huhn, Philipp Reichert, Uta Bertsch, Roland Fenk, Britta Besemer, Amelie Boquoi, Roland Schroers, Ivana von Metzler and 30 more

Erratum issuedAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

40 authors.

Jia Xiang JinHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.ORCID 0000-0001-6574-7816
Varun R GindeDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Stefanie HuhnHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.ORCID 0000-0003-1700-2371
Philipp ReichertHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.ORCID 0000-0001-7583-6222
Uta BertschHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.ORCID 0000-0001-5584-3951
Roland FenkDepartment of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.ORCID 0000-0001-7594-6288
Britta BesemerDepartment of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany.
Amelie BoquoiDepartment for Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.ORCID 0000-0001-8845-3052
Roland SchroersDepartment of Hematology and Oncology, Knappschaft Kliniken, Ruhr-University Bochum, Bochum, Germany.ORCID 0000-0003-2744-5491
Ivana von MetzlerDepartment of Medicine II-Hematology and Oncology, Goethe-University Frankfurt, University Hospital, Frankfurt am Main, Germany.ORCID 0000-0003-1699-4313
Mathias HänelDepartment of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.
Christoph MannDepartment for Hematology, Oncology and Immunology, University Hospital Gießen and Marburg, Marburg, Germany.ORCID 0000-0002-7823-8428
Lisa B LeypoldtDepartment of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-9248-588X
Bernhard HeilmeierClinic for Oncology and Hematology, Hospital Barmherzige Brueder Regensburg, Regensburg, Germany.
Christof ScheidDepartment of Internal Medicine I, University Hospital Cologne, Cologne, Germany.ORCID 0009-0007-6539-226X
Thorsten Peters-RegehrThe Binding Site GmbH, part of Thermo Fisher Scientific, Schwetzingen, Germany.
Igor W BlauMedical Clinic, Charité University Medicine Berlin, Berlin, Germany.
Carsten Müller-TidowHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.ORCID 0000-0002-7166-5232
Steffen LuntzCoordination Centre for Clinical Trials (KKS), University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.ORCID 0000-0002-4696-8792
Tobias A W HolderriedDepartment of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, University Hospital Bonn, Bonn, Germany.ORCID 0000-0002-2474-523X
Karolin Trautmann-GrillDepartment of Internal Medicine I, University Hospital Dresden, TU Dresden, Germany.ORCID 0000-0002-9050-1049
Deniz GezerDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Maika Klaiber-HakimiClinic for Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany.
Martin MüllerClinic for Hematology, Oncology and Immunology, Klinikum Siloah Hannover, Hannover, Germany.
Evgenii ShumilovDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.ORCID 0000-0003-0178-1729
Wolfgang KnaufCenter for Hematology and Oncology Bethanien, Frankfurt am Main, Germany.
Christian S MichelDepartment of Internal Medicine III, University Hospital Mainz, Mainz, Germany.ORCID 0009-0004-1596-3763
Thomas GeerDepartment of Internal Medicine III, Diakoneo Clinic Schwäbisch-Hall, Schwäbisch-Hall, Germany.
Hendrik RiesenbergHematology/Oncology Center, Bielefeld, Germany.
Christoph LutzHematology/Oncology Center, Koblenz, Germany.
Marc S RaabHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.ORCID 0000-0003-4181-6922
Niels WeinholdHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.ORCID 0000-0002-5464-3234
Martin HoffmannMedical Clinic A, Clinic Ludwigshafen, Ludwigshafen, Germany.
Axel BennerDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-7238-6956
Peter FindeisenMVZ Labor Dr Limbach und Kollegen, Heidelberg, Germany.
Katja C WeiselDepartment of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0001-9422-6614
Hans J SalwenderAsklepios Tumorzentrum Hamburg, AK Altona and AK St Georg, Hamburg, Germany.ORCID 0000-0001-7803-0814
Elias K MaiHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.ORCID 0000-0002-6226-1252
Hartmut GoldschmidtHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.ORCID 0000-0003-0961-0035
German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mass spectrometry (MS) offers a minimally invasive approach for detecting monoclonal proteins in multiple myeloma (MM), but large prospective evaluations remain limited. We analyzed 3,301 serum samples from 617 patients enrolled in the phase III GMMG-HD7 trial to characterize the analytical performance and clinical relevance of MS-based measurable residual activity. MS reliably distinguished therapeutic antibodies, tracked diagnostic M proteins longitudinally, and demonstrated strong prognostic value across defined time points. MS negativity was associated with superior progression-free survival (PFS), with the greatest separation at later time points (12 months of maintenance: hazard ratio, 0.25 [95% CI, 0.15 to 0.43]; adjusted

Indexed as

Multiple MyelomaSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorFemaleHumansMyeloma ProteinsNeoplasm, ResidualPrognosisProgression-Free SurvivalAntibodies, MonoclonalBiomarkers, Tumormultiple myeloma M-proteinsMyeloma Proteins

Identifiers

PMID42166704
PMCPMC13440532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.